T cells with chimeric antigen receptors (CARs) have transformed cell therapy and shifted the treatment paradigm for many patients with recurrent or refractory B-cell malignancies. Despite this advancement, CAR-T cell treatment has limits in both autologous and allogeneic contexts, including practical, logistical, and toxicity concerns.
Given these issues, natural killer cells are gaining popularity as an alternate vehicle for CAR creation, thanks to their unique biological characteristics and well-established safety profile in the allogeneic environment.
Article Reference link: click here
Scientific article publishing date: 4/12/2020
Article identifier BSC22_413EN
The foremost Cancer Therapy is here.